Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 8/2017

01.08.2017 | Allergic Skin Diseases (L Fonacier, Section Editor)

Review of Physical Urticarias and Testing Methods

verfasst von: Mario Sánchez-Borges, Luis González-Aveledo, Fernan Caballero-Fonseca, Arnaldo Capriles-Hulett

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to update the information available on the prevalence, clinical picture, diagnostic methods, and treatment of urticarias induced by external physical stimuli.

Recent Findings

Physical urticarias are present in up to 5% of the general population, and in 10 to 50% of patients with chronic urticaria. Recent investigations have provided evidence that the presence of physical urticaria alone or when comorbid with chronic spontaneous urticaria is associated with a worse prognosis and duration.

Summary

Most frequent subtypes of physical urticaria are dermographism and delayed pressure urticaria. The diagnosis is established through specific provocation tests and the management encompasses avoidance measures, pharmacologic therapy with nonsedating antihistamines, and alternative medications in refractory cases.
Literatur
1.
•• Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014: 69: 868–87. Important because this is the current internationally accepted document helpful for the diagnosis and treatment of chronic spontaneous and inducible urticarias.
2.
• Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias—the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780–802. An updated review of all forms of inducible urticarias, especially helpful as a resource on validated diagnostic methods for such diseases CrossRefPubMed
3.
Weller K, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, et al. Chronic urticaria. Prevalence, course, prognostic factors and impact. Hautarzt. 2010;61:750–7.CrossRefPubMed
4.
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Subtypes of chronic urticaria in patients attending allergy clinics in Venezuela. Eur Ann Allergy Clin Immunol. 2014;46:210–5.PubMed
5.
• Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317–30. Here authors indicate areas of uncertain knowledge for understanding chronic urticaria that need further investigation CrossRefPubMed
6.
Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013;68:229–35.CrossRefPubMed
7.
• Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L, Maurer M. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017; doi:10.​1111/​jdv.​ 14221. This paper highlights that the presence of physical urticaria confers a worse prognosis for patients with urticaria
8.
Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387–91.CrossRefPubMed
9.
Dice JP. Physical urticaria. Immunol Allergy Clin N Am. 2004;24:225–46.CrossRef
10.
Trevisonno J, Balram B, Netchiporouk E, Ben-Shoshan M. Physical urticaria: review on classification, triggers and management with special focus on prevalence including a meta-analysis. Postgrad Med. 2015;127:565–70.CrossRefPubMed
11.
Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol. 1993;29:954–8.CrossRefPubMed
12.
Katsarou-Katsari A, Makris M, Lagogianni E, Gregoriou S, Theoharides T, Kalogeromitros D. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. J Eur Acad Dermatol Venereol. 2008;22:1405–11.CrossRefPubMed
13.
Chong WS, Khoo SW. Solar urticaria in Singapore: an uncommon photodermatosis seen in a tertiary dermatology center over a 10-year period. Photodermatol Photoimmunol Photomed. 2004;20:101–4.CrossRefPubMed
14.
Carrillo DC, Sánchez-Borges M, García E, Egea E, Serrano CD. Omalizumab vs placebo in the management of chronic idiopathic urticaria: a systematic review. World Allergy Organ J. 2014;7:72.CrossRefPubMedPubMedCentral
15.
•• Sánchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, Gower R, Kahn DA, Kaplan AP, Katelaris C, Maurer M, Park HS, Potter P, Saini S, Tassinari P, Tedeschi A, Ye YM, Zuberbier T; WAO Scientific and Clinical Issues Council. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012: 5: 125–47. A review of chronic urticaria with recommendations for its treatment according to evidence based medicine.
16.
Leigh IM, Ramsay CA, Calnan CD. Cold urticaria—‘desensitisation’. Trans St Johns Hosp Dermatol Soc. 1979;60:40–2.
17.
Black AK, Sibbald RG, Greaves MW. Cold urticaria treated by induction of tolerance. Lancet. 1979;2:964.CrossRefPubMed
18.
Leigh IM, Ramsay CA. Localized heat urticaria treated by inducing tolerance to heat. Br J Dermatol. 1975;92:191–4.CrossRefPubMed
19.
Ramsay CA. Solar urticaria treatment by inducing tolerance to artificial radiation and natural light. Arch Dermatol. 1977;113:1222–5.CrossRefPubMed
20.
Soter NA, Wasserman SI. Physical urticaria/angioedema: an experimental model of mast cell activation in humans. J Allergy Clin Immunol. 1980;66:358–65.CrossRefPubMed
21.
Krause K, Ardelean E, Kessler B, Magerl M, Metz M, Siebenhaar F, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65:1494–5.CrossRefPubMed
22.
Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177–80.CrossRefPubMed
23.
Toda S, Takahagi S, Mihara S, Hide M. Six cases of antihistamine-resistant dermographic urticaria treated with oral ciclosporin. Allergol Int. 2011;60:547–50.CrossRefPubMed
24.
Borzova E, Rutherford A, Konstantinou GN, Leslie KS, Grattan CE. Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. J Am Acad Dermatol. 2008;59:752–7.CrossRefPubMed
25.
Johnsson M, Falk ES, Volden G. UVB treatment of factitious urticaria. Photo-Dermatology. 1987;4:302–4.PubMed
26.
Barlow RJ, Ross EL, MacDonald D, Black AK, Greaves MW. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol. 1994;131:341–7.CrossRefPubMed
27.
Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;155:1279–82.CrossRefPubMed
28.
Rodríguez-Rodríguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sánchez-González MJ, Alvarez-Mon M. Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immunopathol. 2014;42:78–80.CrossRef
29.
Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65:138–9.CrossRefPubMed
30.
Grundmann SA, Kiefer S, Luger TA, Brehler R. Delayed pressure urticaria—dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011;9:908–12.PubMed
31.
Swerlick RA, Puar N. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients. Dermatol Ther. 2015;28:318–22.CrossRefPubMed
32.
Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol. 2007;119:752–4.CrossRefPubMed
33.
Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, Gregoriou S, Makris M, Boucher W, et al. Theophylline as “add-on” therapy in patients with delayed pressure urticaria: a prospective self-controlled study. Int J Immunopathol Pharmacol. 2005;18:595–602.CrossRefPubMed
34.
Wanderer AA, Grandel KE, Wasserman SI, Farr RS. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. J Allergy Clin Immunol. 1986;78:417–23.CrossRefPubMed
35.
36.
Kaplan AP, Gray L, Shaff RE, Horakova Z, Beaven MA. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol. 1975;55:394–402.CrossRefPubMed
37.
Stankovic K, Grateau G. Auto inflammatory syndromes: diagnosis and treatment. Joint Bone Spine. 2007;74:544–50.CrossRefPubMed
38.
Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. New Engl J Med. 2012;366:330–8.CrossRefPubMedPubMedCentral
39.
Kolivras A, Theunis A, Ferster A, Lipsker D, Sass U, Dussart A, et al. Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J Cutan Pathol. 2011;38:202–8.CrossRefPubMed
40.
Aróstegui JI, Aldea A, Modesto C, Rua MJ, Argüelles F, González-Enseñat MA, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum. 2004;50:4045–50.CrossRefPubMed
41.
Wanderer AA, Grandel KE, Wasserman SI, Farr RS. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. Immunol Allergy Clin N Am. 2004;24:259–86.CrossRef
42.
Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001;108:615–20.CrossRefPubMedPubMedCentral
43.
Martinez-Escala ME, Curto-Barredo L, Carnero L, Pujol RM, Giménez-Arnau AM. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol. 2015;95:278–82.CrossRefPubMed
44.
Magerl M, Abajian M, Krause K, Altrichter S, Siebenhaar F, Church MK. An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. J Eur Acad Dermatol Venereol. 2015;29:2043–5.CrossRefPubMed
45.
• Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672–9. A study showing improvement of cold urticaria with increased doses of nonsedating antihistamines CrossRefPubMed
46.
• Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68:921–8. Confirmation of the usefulness of increased doses of bilastine in patients with acquired cold urticaria CrossRefPubMedPubMedCentral
47.
Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415–8.CrossRefPubMed
48.
Möller A, Henning M, Zuberbier T, Czarnetzki-Henz BM. Epidemiology and clinical aspects of cold urticaria. Hautarzt. 1996;47:510–4.CrossRefPubMed
49.
Bodar EJ, Simon A, de Visser M, van der Meer JW. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med. 2009;67:302–5.PubMed
50.
Gualdi G, Monari P, Rossi MT, Crotti S, Calzavara-Pinton PG. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Br J Dermatol. 2012;166:1373–4.CrossRefPubMed
51.
Bentley-Phillips CB, Black AK, Greaves MW. Induced tolerance in cold urticaria caused by cold-evoked histamine release. Lancet. 1976;2:63–6.CrossRefPubMed
52.
Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, Maurer M, Bindslev-Jensen C. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology. 2012;224:101–5.CrossRefPubMed
53.
Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65:931–2.CrossRefPubMed
54.
Carballada F, Nuñez R, Martin-Lazaro J, Juárez Y, Castiñeira I, Carballada F, et al. Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergy Clin Immunol. 2013;23:519–21.
55.
56.
57.
Duchini G, Bäumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed. 2011;27:336–7.CrossRefPubMed
58.
Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F, et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatric Allergy Immunol. 2015;26:583–5.CrossRef
59.
Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatric Allergy Immunol. 2015;26:588–90.CrossRef
60.
Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563–5.CrossRefPubMed
61.
Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010;125:490–1.CrossRefPubMed
62.
Edström DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed. 1997;13:61–3.CrossRefPubMed
63.
Puech-Plottova I, Michel JL, Rouchouse B, Perrot JL, Dzviga C, Cambazard F. Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol. 2000;127:831–5.PubMed
64.
Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol. 2011;164:407–14.CrossRefPubMed
65.
Roelandts R. Pre-PUVA UVA desensitization for solar urticaria. Photo-Dermatology. 1985;2:174–6.PubMed
66.
Hudson-Peacock MJ, Farr PM, Diffey BL, Goodship TH. Combined treatment of solar urticaria with plasmapheresis and PUVA. Br J Dermatol. 1993;128:440–2.CrossRefPubMed
67.
Duschet P, Leyen P, Schwarz T, Höcker P, Greiter J, Gschnait F. Solar urticaria: treatment by plasmapheresis. J Am Acad Dermatol. 1986;15:712–3.CrossRefPubMed
68.
69.
Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42:1030–2.CrossRefPubMed
70.
Hölzle E, Hofmann C, Plewig G. PUVA-treatment for solar urticaria and persistent light reaction. Arch Dermatol Res. 1980;269:87–91.CrossRefPubMed
71.
Epstein PA, Kidd KK. Dermo-distortive urticaria: an autosomal dominant dermatologic disorder. Am J Med Genet. 1981;9:307–15.CrossRefPubMed
72.
Pressler A, Grosber M, Halle M, Ring J, Brockow K. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol. 2013;38:151–3.CrossRefPubMed
73.
Ting S, Reimann BE, Rauls DO, Mansfield LE. Nonfamilial, vibration-induced angioedema. J Allergy Clin Immunol. 1983;71:546–51.CrossRefPubMed
74.
Fukunaga A, Bito T, Tsuru K, Oohashi A, Yu X, Ichihashi M, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol. 2005;116:397–402.CrossRefPubMed
75.
Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12:406–11.CrossRefPubMed
76.
Seize MB, Ianhez M, de Souza PK, Rotta O, Cestari CS. Familial aquagenic urticaria: report of two cases and literatura review. An Bras Dermatol. 2009;84:530–3.CrossRefPubMed
77.
Parker RK, Crowe MJ, Guin JD. Aquagenic urticaria. Cutis. 1992;50:283–4.PubMed
78.
Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol. 1997;36:118–9.CrossRefPubMed
79.
Bayle P, Gadroy A, Messer L, Basex J. Localized aquagenic urticaria: efficacy of a barrier cream. Contact Dermatitis. 2003;49:160–1.CrossRefPubMed
Metadaten
Titel
Review of Physical Urticarias and Testing Methods
verfasst von
Mario Sánchez-Borges
Luis González-Aveledo
Fernan Caballero-Fonseca
Arnaldo Capriles-Hulett
Publikationsdatum
01.08.2017
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 8/2017
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-017-0722-1

Weitere Artikel der Ausgabe 8/2017

Current Allergy and Asthma Reports 8/2017 Zur Ausgabe

Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Update on Quinolone Allergy

Immune Deficiency and Dysregulation (DP Huston and C Kuo, Section Editors)

Inflammatory Bowel Disease in Primary Immunodeficiencies

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Eosinophilic Esophagitis in Children

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Tobacco Use and Smoke Exposure in Children: New Trends, Harm, and Strategies to Improve Health Outcomes

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Primary Prevention of Food Allergy

Allergies and the Environment (M Hernandez, Section Editor)

Role of Obesity in Asthma: Mechanisms and Management Strategies

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Tonsillektomie | Nachrichten

Intrakapsuläre Tonsillektomie gewinnt an Boden

15.04.2024 | Hörsturz | Nachrichten

Bilateraler Hörsturz hat eine schlechte Prognose

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“
weitere anzeigen

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen